| 1. |
- Banerjee, Antara, et al.
(författare)
-
Role of Tumor Specific niche in Colon Cancer Progression and Emerging Therapies by Targeting Tumor Microenvironment
- 2021. - 1
-
Ingår i: Cell Biology and Translational Medicine, Volume 13. - Cham : Springer. - 9783030790578 - 9783030790585 ; , s. 177-192
-
Bokkapitel (refereegranskat)abstract
- Colorectal cancer is the third most common form of cancer worldwide leading to escalating mortality rates and mainly includes hereditary, sporadic and colitis-associated cancer development. The escalated mortality rates is due to the limited treatment options as this form of cancer is usually not easy to diagnose in its early stages and are highly invasive leading to rapid metastasis of the malignant cells to the neighbouring tissue. In order to combat this limitation several chemotherapeutic regimens are now being combined with targeted therapies after the knowledge acquired on the inevitable effects of the tumor microenvironment on the colon cancer growth and progress. The colon tumor niche mainly consists of a large mass of tumor cells along with various immune cells, inflammatory cells, tumor macrophages and fibroblasts that infiltrate the tumor as it is a site of predominant inflammation. Among cells of the microenvironment, mesenchymal stem cells (MSCs) exhibiting ability to evolve into cancer associated fibroblasts (CAFs) have recently generated a major interest in the field. The physiological state of the tumor microenvironment is closely connected to discrete steps of tumorigenesis. The colon cancer cells elicit various factors with their direct interaction with MSCs or via paracrine fashion, which modulate these cells to promote cancer instead of performing their innate function of abating cancer progression. This review intends to highlight the necessity to exploit the cellular landscape of tumor microenvironment of colon cancer and a detailed understanding of the interactions between tumor epithelial cells and their stromal/inflammatory elements will aid in future perspectives for designing therapeutic regimens targeting tumor microenvironment to improve the clinical outcome of colon cancer.
|
|
| 2. |
|
|
| 3. |
- Bengtsson, Tommy, et al.
(författare)
-
Economic Stress and Reproductive Responses
- 2010
-
Ingår i: Prudence and Pressure. Reproduction and Human Agency in Europe and Asia, 1700-1900.
-
Bokkapitel (övrigt vetenskapligt/konstnärligt)
|
|
| 4. |
- Brink, Lars, 1943, et al.
(författare)
-
Preface
- 2022
-
Ingår i: Looking Beyond the Frontiers of Science: Dedicated to the 80th Birthday of K.K. Phua. - : WORLD SCIENTIFIC. ; , s. v-vi
-
Bokkapitel (övrigt vetenskapligt/konstnärligt)
|
|
| 5. |
- Shruthi, N. R., et al.
(författare)
-
Drug Repurposing in Cancer
- 2023. - 1
-
Ingår i: Drug Repurposing for Emerging Infectious Diseases and Cancer. - Singapore : Springer. - 9789811953989 - 9789811953996 ; , s. 159-179
-
Bokkapitel (övrigt vetenskapligt/konstnärligt)abstract
- The discovery of drug compounds has a long history in drug repurposing, notably by fortuitous findings. It has taken a new path in the creation of novel therapeutics based on existent or authorized drugs in recent years. Importantly, our knowledge of cancer biology and the related cancer hallmarks is growing. This, together with repurposing studies that use modern bioinformatics and comprehensive screening of the complete pharmacopeia, should lead to the discovery of novel medicines and targets. Furthermore, the usage of non-oncology pharmaceuticals, which make up most of our treatments, has the potential to speed up drug repurposing even further. We looked at both phenotypic-based and target-based methods of medication repurposing as well as described and assessed old non-oncology medications as prospective candidates for drug repurposing based on a broad knowledge of these principles and associated investigations of drug repurposing over the previous decade. Some of these medications successfully regulate at least one characteristic of cancer, whereas the others have a broad anticancer activity by regulating several targets through different signaling pathways, which is often brought on by various simultaneous signaling pathways. Furthermore, the emergence of computerized databases of disease gene targets, functional readouts, and clinical data encompassing inter-individual genetic variants and toxicities has allowed an alternative “big data” approach to grow at an unheard-of rate during the past decade. Here, we review the sources that are now on hand and speculate on significant upside possibilities.
|
|
